Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Diabetes and Endocrinology
  • Diabetes and Endocrinology News
  • Gliclazide modified...

Gliclazide modified release better second-line treatment than sitagliptin for type 2 diabetes patients on Metformin- Study

Written By : Hina Zahid |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2020-10-09T09:44:08+05:30  |  Updated On 9 Oct 2020 2:37 PM IST
Gliclazide modified release better second-line treatment than sitagliptin for type 2 diabetes patients on Metformin- Study
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

UK: Gliclazide modified release (MR) is more effective in reducing blood sugar levels than sitagliptin in type 2 diabetes (T2D) patients already taking metformin, a recent study published in the journal Diabetes, Obesity and Metabolism has pointed out.

Gliclazide MR is available in India as Gliclazide XR (Extended Release) tablets

Type 2 diabetes is a chronic metabolic disorder that results from the ineffective use of insulin by the body. It is characterized by high levels of blood glucose and is associate with long-term micro and macrovascular complications. These complications increase the burden for both the treatment costs and the patient's health. Glucose-lowering medications are aimed at maintaining optimal blood glucose levels while reducing the risk of risk of hypoglycaemic events.
International guidelines recommend individualized glycemic control in T2D patients for reducing long-term risks of microvascular and macrovascular complications. Current T2D guidelines recommend the addition of a second medication to ensure glycemic control in patients whose blood glucose remains high after evidenced‐based patient education, dietary advice, and first‐line therapy of Metformin. Recent reports in UK have found sulfonylureas (SUs) such as Gliclazide MR and DPP‐4 inhibitors such as sitagliptin to be the most commonly prescribed second-line diabetes treatments.
Although many studies have compared the general classes of treatments such as SUs and DPP-4 inhibitors with other classes or individual medications, the properties of individual medications in a class can vary. Therefore, there has been a need for studies comparing the effectiveness of individual medications to assist in informed decision making.
Thus, a first real-world study comparing the two drugs, supported by Servier, was conducted by the team of Professor Kamlesh Khunti from the University of Leicester, UK.
The aim of this study was to evaluate the effectiveness, in a real-world situation, of two oral antidiabetic treatments - gliclazide MR and sitagliptin - in second-line treatment after metformin, in patients with uncontrolled type 2 diabetes. The study was conducted on a nine-year retrospective cohort, using data from the Clinical Practice Research Datalink (CPRD) database in the UK, in adult patients with type 2 diabetes and a glycated hemoglobin (HbA1c) level greater than 7.0%
Adult patients (≥18 years old), with a documented diagnosis of T2D, ≥1 year of up- to-standard follow-up (i.e., ≥1 year from the date the practice data meet minimum quality criteria for research), at least one HbA1c measurement ≥7% in the 6 months prior to entry were included in the study. Patients with a diagnosis of type 1 or any other specific diabetes (e.g. gestational, secondary, steroid, mature onset diabetes of the young, etc.) were excluded.
Patients were matched 1:1 using high‐dimensional propensity score matching. They were then followed to determine the time taken to reach an HbA1c <7.0%.
Secondary outcomes included time to HbA1c ≤6.5%, time to ≥1% HbA1c reduction from baseline, treatment persistence and durability, and hypoglycaemic events.
Total of 1986 patients including 993 patients in each group with a treatment duration were followed up to 9 years for outcome analysis
Key findings of the study showed:
• Overall, patients treated with gliclazide MR were 35% more likely to achieve the target of <7.0% HbA1c than patients in the sitagliptin group.
• Patients treated with gliclazide MR were 51% more likely to achieve the target of HbA1c ≤6.5%
• Patients treated with gliclazide MR were also 11% more likely to achieve an HbA1c reduction of ≥1% from baseline
• This difference between gliclazide MR and sitagliptin was consistent regardless of baseline HbA1c and age if the patient.
• Durability and persistence, which represent treatment duration were similar between the two groups.
• In general, each group demonstrated low rates of hypoglycemia throughout the study. Hypoglycaemic events were uncommon (23 total severe and non‐severe events; incidence rate, 3.7 per 1000 patient-years).
This first real-world study highlighted very positive results that reinforce the role of Gliclazide MR as a second-line treatment option for patients with uncontrolled type 2 diabetes on metformin therapy. Real-world patients with gliclazide MR led to a greater probability of patients achieving HbA1c <7.0% and ≤6.5% , with a treatment effect already evident at 3 months.This rapid reduction of HbA1c levels may help prevent long-term risk of complications. "In this real-world study, second-line gliclazide MR was more effective than sitagliptin in reducing HbA1c, with similar durability and persistence and low rates of hypoglycaemic events, in individuals with T2D on metformin treatment and HbA1c above the target of 7.0%.," wrote the authors.
To read the full study, click on the following link
https://dompubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.14169

gliclazidesitagliptintype 2 diabetesmetformindiabetes obesity and metabolismdiabetesUKCPRD
Hina Zahid
Hina Zahid

    Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    View All

    Journal Club Today

    Global Omega-3 Shortage Poses Serious Health and Environmental Risks: Study

    Global Omega-3 Shortage Poses Serious Health and Environmental Risks: Study

    View All

    Health News Today

    Health Bulletin 31/May/2025

    Health Bulletin 31/May/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok